Picture of Adaptimmune Therapeutics logo

ADAP Adaptimmune Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Adaptimmune Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-137-130-158-165-114
Depreciation
Amortisation
Non-Cash Items11.912.927.619.1-11.9
Unusual Items
Other Non-Cash Items
Changes in Working Capital4.7256135-1.53-25
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Cash from Operating Activities-113-53.610.7-142-141
Capital Expenditures-3.07-2.91-8.78-29.7-4.88
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items98-27684.6119181
Sale of Business
Sale/Maturity of Investment
Change in Net Investments
Other Investing Cash Flow
Cash from Investing Activities94.9-27975.889.1177
Net Issuance / Retirement of Stock
Cash from Financing Activities0.3663403.2912.90.88
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-17.66.5890.2-42.137.4